- Home
- CATX vs CRBU Comparison
CATX vs CRBU Comparison
Compare CATX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | CRBU |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.1M | 203.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CATX | CRBU |
|---|---|---|
| Price | $2.70 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $11.56 | $8.50 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 11-10-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,075,000.00 | ★ $9,295,000.00 |
| Revenue This Year | N/A | $0.22 |
| Revenue Next Year | N/A | $4.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $0.66 |
| 52 Week High | $5.39 | $3.54 |
Technical Indicators
Market Signals| Indicator | CATX | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 48.31 |
| Support Level | $2.25 | $1.39 |
| Resistance Level | $2.66 | $1.63 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 60.56 | 56.59 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.